These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 19732452)

  • 1. Reversal of oncogene transformation and suppression of tumor growth by the novel IGF1R kinase inhibitor A-928605.
    Pappano WN; Jung PM; Meulbroek JA; Wang YC; Hubbard RD; Zhang Q; Grudzien MM; Soni NB; Johnson EF; Sheppard GS; Donawho C; Buchanan FG; Davidsen SK; Bell RL; Wang J
    BMC Cancer; 2009 Sep; 9():314. PubMed ID: 19732452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma.
    May CD; Landers SM; Bolshakov S; Ma X; Ingram DR; Kivlin CM; Watson KL; Sannaa GAA; Bhalla AD; Wang WL; Lazar AJ; Torres KE
    Cancer Biol Ther; 2017 Oct; 18(10):816-826. PubMed ID: 29099264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
    Park JH; Choi YJ; Kim SY; Lee JE; Sung KJ; Park S; Kim WS; Song JS; Choi CM; Sung YH; Rho JK; Lee JC
    Oncotarget; 2016 Apr; 7(16):22005-15. PubMed ID: 26980747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.
    Ji QS; Mulvihill MJ; Rosenfeld-Franklin M; Cooke A; Feng L; Mak G; O'Connor M; Yao Y; Pirritt C; Buck E; Eyzaguirre A; Arnold LD; Gibson NW; Pachter JA
    Mol Cancer Ther; 2007 Aug; 6(8):2158-67. PubMed ID: 17671083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer.
    Liu F; Liu Y; Liu X; Mao K; Zhong D; Marcus AI; Khuri FR; Sun SY; He Y; Zhou W
    Lung Cancer; 2018 Sep; 123():36-43. PubMed ID: 30089593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of E-cadherin Enhances IGF1-IGF1R Pathway Activation and Sensitizes Breast Cancers to Anti-IGF1R/InsR Inhibitors.
    Nagle AM; Levine KM; Tasdemir N; Scott JA; Burlbaugh K; Kehm J; Katz TA; Boone DN; Jacobsen BM; Atkinson JM; Oesterreich S; Lee AV
    Clin Cancer Res; 2018 Oct; 24(20):5165-5177. PubMed ID: 29941485
    [No Abstract]   [Full Text] [Related]  

  • 7. Insulin-like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract cancers.
    Ohashi H; Adachi Y; Yamamoto H; Taniguchi H; Nosho K; Suzuki H; Arimura Y; Imai K; Carbone DP; Shinomura Y
    Cancer Sci; 2012 Feb; 103(2):252-61. PubMed ID: 22044563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity.
    Lee HJ; Pham PC; Hyun SY; Baek B; Kim B; Kim Y; Min HY; Lee J; Lee HY
    Mol Cancer; 2018 Feb; 17(1):50. PubMed ID: 29455661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase.
    Sabbatini P; Rowand JL; Groy A; Korenchuk S; Liu Q; Atkins C; Dumble M; Yang J; Anderson K; Wilson BJ; Emmitte KA; Rabindran SK; Kumar R
    Clin Cancer Res; 2009 May; 15(9):3058-67. PubMed ID: 19383820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The IGF2/IR/IGF1R Pathway in Tumor Cells and Myofibroblasts Mediates Resistance to EGFR Inhibition in Cholangiocarcinoma.
    Vaquero J; Lobe C; Tahraoui S; Clapéron A; Mergey M; Merabtene F; Wendum D; Coulouarn C; Housset C; Desbois-Mouthon C; Praz F; Fouassier L
    Clin Cancer Res; 2018 Sep; 24(17):4282-4296. PubMed ID: 29716918
    [No Abstract]   [Full Text] [Related]  

  • 11. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.
    Feng S; Shao L; Castro P; Coleman I; Nelson PS; Smith PD; Davies BR; Ittmann M
    Oncotarget; 2017 Jan; 8(4):6179-6192. PubMed ID: 28008155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Supersulfated low-molecular weight heparin synergizes with IGF1R/IR inhibitor to suppress synovial sarcoma growth and metastases.
    Cassinelli G; Dal Bo L; Favini E; Cominetti D; Pozzi S; Tortoreto M; De Cesare M; Lecis D; Scanziani E; Minoli L; Naggi A; Vlodavsky I; Zaffaroni N; Lanzi C
    Cancer Lett; 2018 Feb; 415():187-197. PubMed ID: 29225052
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Panebianco F; Kelly LM; Liu P; Zhong S; Dacic S; Wang X; Singhi AD; Dhir R; Chiosea SI; Kuan SF; Bhargava R; Dabbs D; Trivedi S; Gandhi M; Diaz R; Wald AI; Carty SE; Ferris RL; Lee AV; Nikiforova MN; Nikiforov YE
    Proc Natl Acad Sci U S A; 2017 Feb; 114(9):2307-2312. PubMed ID: 28193878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.
    Lee Y; Wang Y; James M; Jeong JH; You M
    Mol Carcinog; 2016 May; 55(5):991-1001. PubMed ID: 26052929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The TGFβ pathway stimulates ovarian cancer cell proliferation by increasing IGF1R levels.
    Alsina-Sanchis E; Figueras A; Lahiguera Á; Vidal A; Casanovas O; Graupera M; Villanueva A; Viñals F
    Int J Cancer; 2016 Oct; 139(8):1894-903. PubMed ID: 27299695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas.
    Piao W; Wang Y; Adachi Y; Yamamoto H; Li R; Imsumran A; Li H; Maehata T; Ii M; Arimura Y; Lee CT; Shinomura Y; Carbone DP; Imai K
    Mol Cancer Ther; 2008 Jun; 7(6):1483-93. PubMed ID: 18566219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis.
    Sanderson MP; Apgar J; Garin-Chesa P; Hofmann MH; Kessler D; Quant J; Savchenko A; Schaaf O; Treu M; Tye H; Zahn SK; Zoephel A; Haaksma E; Adolf GR; Kraut N
    Mol Cancer Ther; 2015 Dec; 14(12):2762-72. PubMed ID: 26438154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the Oncogenic Transcriptional Regulator MYB in Adenoid Cystic Carcinoma by Inhibition of IGF1R/AKT Signaling.
    Andersson MK; Afshari MK; Andrén Y; Wick MJ; Stenman G
    J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28954282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
    Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
    Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.
    Qi W; Cooke LS; Stejskal A; Riley C; Croce KD; Saldanha JW; Bearss D; Mahadevan D
    BMC Cancer; 2009 May; 9():142. PubMed ID: 19432987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.